Literature DB >> 2730852

Frozen section control of excision of eyelid basal cell carcinomas: 8 1/2 years' experience.

H J Frank1.   

Abstract

For a period of 8 1/2 years all basal cell carcinomas were excised under frozen section control. One hundred and fifty-six patients with 165 tumours were treated, and 137 were followed up for at least three months (3-94 months, mean 29.1 months). There were three possible recurrences, giving a recurrence rate of up to 2.19%. The practical implications, advantages, and difficulties encountered are described, and the place of frozen section control of excision of basal cell carcinoma in a busy NHS general ophthalmic practice is discussed.

Entities:  

Mesh:

Year:  1989        PMID: 2730852      PMCID: PMC1041733          DOI: 10.1136/bjo.73.5.328

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  Low incidence of recurrence in excised but non-irradiated basal cell carcinomas.

Authors:  J H Binns; H M Sherriff
Journal:  Br J Plast Surg       Date:  1975-04

2.  Observations on the treatment of basal cell carcinoma of the eyelids. The Wendell L. Huges Lecture.

Authors:  C Beard
Journal:  Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol       Date:  1975 Sep-Oct

3.  Surgery of basal-cell carcinoma.

Authors:  B K RANK; A R WAKEFIELD
Journal:  Br J Surg       Date:  1958-03-18       Impact factor: 6.939

4.  Basal cell carcinoma in the eyelid region.

Authors:  J R Collin
Journal:  Br J Ophthalmol       Date:  1976-12       Impact factor: 4.638

5.  The adequacy of the surgical excision of basal cell carcinoma.

Authors:  S I Rakofsky
Journal:  Ann Ophthalmol       Date:  1973-05

6.  Reappraisal of basal cell carcinoma of the eyelids.

Authors:  A L Aurora; F C Blodi
Journal:  Am J Ophthalmol       Date:  1970-09       Impact factor: 5.258

7.  Basal cell carcinoma of the eyelids. A long-term follow-up study.

Authors:  J W Payne; J R Duke; R Butner; D E Eifrig
Journal:  Arch Ophthalmol       Date:  1969-04

8.  Frozen section control in the surgery of basal cell carcinoma of the eyelid.

Authors:  J Chalfin; A M Putterman
Journal:  Am J Ophthalmol       Date:  1979-06       Impact factor: 5.258

9.  Factors in the successful surgical management of basal cell carcinoma of the eyelids.

Authors:  M T Doxanas; W R Green; C E Iliff
Journal:  Am J Ophthalmol       Date:  1981-06       Impact factor: 5.258

10.  Surgical removal of basal cell carcinoma of the eyelids utilizing frozen section control.

Authors:  J J Older; M H Quickert; C Beard
Journal:  Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol       Date:  1975 Sep-Oct
  10 in total
  6 in total

1.  The optimal follow-up time for a basal cell carcinoma of the eyelid.

Authors:  J W Tijl; L Koornneff
Journal:  Doc Ophthalmol       Date:  1990-10       Impact factor: 2.379

2.  Malignant eyelid tumors: Are intra-operative rapid frozen section and permanent section diagnoses of surgical margins concordant?

Authors:  Swathi Kaliki; Sasi Pyda; Nupur Goel; Tarjani Vivek Dave; Milind N Naik; Dilip K Mishra
Journal:  Int Ophthalmol       Date:  2018-12-08       Impact factor: 2.031

3.  5 years review of periocular basal cell carcinoma and proposed follow-up protocol.

Authors:  S F Ho; L Brown; M Bamford; R Sampath; J Burns
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

4.  A reappraisal of cryosurgery for eyelid basal cell carcinomas.

Authors:  W Buschmann
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

5.  Surgery for primary basal cell carcinoma including the eyelid margins with intraoperative frozen section control: comparative interventional study with a minimum clinical follow up of 5 years.

Authors:  R M Conway; S Themel; L M Holbach
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

6.  The treatment of periocular basal cell carcinomas by radiotherapy.

Authors:  J M Rodriguez; G P Deutsch
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.